Printer Friendly

NOVA PHARMACEUTICAL SEEKS FDA APPROVAL TO BEGIN HUMAN TESTING OF A NEW TREATMENT FOR SEPSIS AND SEPTIC SHOCK

 NOVA PHARMACEUTICAL SEEKS FDA APPROVAL TO BEGIN
 HUMAN TESTING OF A NEW TREATMENT FOR SEPSIS AND SEPTIC SHOCK
 BALTIMORE, Dec. 30 /PRNewswire/ -- Nova Pharmaceutical Corporation (NASDAQ: NOVX) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) seeking approval to conduct human clinical trials of the company's leumedin anti-inflammatory compound, NPC 15669, for the treatment of sepsis and septic shock. Upon approval of the IND application, Nova intends to begin Phase I safety studies.
 Nova is developing leumedin compounds to treat several inflammatory conditions. Septic shock is an inflammatory condition which occurs following overwhelming bacterial infection (called sepsis) and is characterized by fever, low white blood cell count, low blood pressure, and multiple organ failure. In preclinical models, the leumedin compound NPC 15669 has been shown to be active against an experimental form of septic shock. Each year, approximately 400,000 patients in the United States develop sepsis, which is a leading cause of mortality among hospitalized patients.
 Nova Pharmaceutical Corporation, based in Baltimore, is engaged in the discovery, development, and commercialization of pharmaceutical products which address areas of significant medical need. The company's research and development programs are in three principal areas: inflammation, central nervous system disorders, and drug delivery systems.
 -0- 12/30/91
 /CONTACT: Kira Bacon of Nova Pharmaceutical, 410-558-9465, or Noonan/Russo Communications, 212-979-9180, for Nova Pharmaceutical/
 (NOVX) CO: Nova Pharmaceutical Corporation ST: Maryland IN: MTC SU:


JT-OS -- NY014 -- 5627 12/30/91 11:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 30, 1991
Words:251
Previous Article:HEALTHCARE COSTS INCREASE AT ALARMING RATE FOR 1991 AND BEYOND, REPORTS BLUE CROSS AND BLUE SHIELD OF NORTH CAROLINA
Next Article:ROBERT C. LAMB, JR. NAMED SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER AT RECOLL MANAGEMENT CORP.
Topics:


Related Articles
CENTOXIN IS APPROVED IN FRANCE
NOVA PHARMACEUTICAL ISSUED A PATENT FOR A CLASS OF LEUMEDIN COMPOUNDS
SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
NOVA PHARMACEUTICAL BEGINS HUMAN TESTING ON TREATMENT FOR INFLAMMATORY CONDITIONS; TARGET SEPSIS/SEPTIC SHOCK, INFLAMMATORY BOWEL DISEASE
IMMUNEX BEGINS SOLUBLE TNF RECEPTOR TRIALS; NIH LAUNCHES FIRST STUDY IN SEPSIS PATIENTS
SCIOS NOVA ANNOUNCES FORMATION OF GUILFORD PHARMACEUTICALS; GUILFORD TO DEVELOP TREATMENTS FOR NEUROLOGICAL AND PSYCHIATRIC DISEASES
Bayer Corporation Announces NORASEPT II Results at the American College of Chest Physician's 63rd Annual International Scientific Assembly
Eli Lilly's Xigris Could Lead the Way in Revolutionizing the Treatment Of Severe Sepsis and Septic Shock, According to a Decision Resources Study.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters